RECEIVED
CENTRAL FAX CENTER
FFR 2 2 2000

Atty Dkt. No.: PT2099001 USSN: 10/523,761

## AMENDMENTS TO THE CLAIMS

The following Listing of Claims, in which deleted text appears struck through and inserted text appears underlined, will replace all prior versions, and listings, of the claims in the application.

## Listing of Claims:

1.(Previously Presented) A composition for oral administration which achieves drug release in two spikes, said composition comprising a single population of uncoated particles of a homogenous mixture consisting essentially of a water-soluble drug and an enteric polymer, wherein the ratio of enteric polymer to the water-soluble drug in the single population is greater than 4 and less than 100.

## 2. (Canceled)

- 3.(Previously presented) The composition of claim 1 wherein the ratio of enteric polymer to the water-soluble drug is greater than 4 and less then 50.
- 4.(Previously presented) The composition of claim 1 wherein the ratio of enteric polymer to drug is from about 10 to about 20.
- 5.(Previously presented) The composition of claims 1, 3 or 4 wherein said particles of the composition further comprise granules sized so as to pass through a #8 mesh screen but which do not pass through a #16 mesh screen.

## 6. (Canceled)

7.(Previously presented) The composition of claim 5 wherein about 50 % of water-soluble drug releases in gastric fluid and the balance of the water-soluble drug releases in

P.8/15

Atty Dkt. No.: PT2099001 USSN: 10/523,761

intestinal fluid.

8.(Previously presented) The composition of claim 7 wherein the water-soluble drug is

methylphenidate or a salt thereof.

9.(Previously presented) The composition of claim 8 wherein the enteric polymer is

polyvinyl acetate phthalate.

10.(Previously presented) A composition for oral administration which achieves drug

release in two spikes, said composition comprising a single population of uncoated particles of a

homogenous mixture consisting essentially of methylphenidate or a salt thereof and an enteric

polymer, wherein the ratio of enteric polymer to methylphenidate or a salt thereof in the single

population is greater than 10 and less than 50 wherein said uncoated particles of the composition

further comprise granules sized so as to pass through a #8 mesh screen which do not pass

through a #16 mesh screen.

11.(Previously presented) The composition of claim 10 wherein the enteric polymer is

polyvinyl acetate phthalate.